As we bring back Managed Healthcare Executive's "Meet the Board" podcast series, MHE welcomes its newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx.
As we bring back our "Meet the Board" Series podcast series, Managed Healthcare Executive welcomes our newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx. In this conversation, Baker and Peter Wehrwein, MHE managing editor, discussed insights from Baker's career journey, particularly his tenure at Walgreens, where he gained insights into operational efficiency and patient care.
Baker highlighted the importance of process orientation and patient-centered care, drawing from his experience as a pharmacist.
He also dove into his time at Premise Health, highlighting their service-oriented model focused on improving adherence and patient outcomes. He contrasted this with traditional PBMs' profit-driven approaches, expressing concerns about opaque pricing practices and exclusionary formularies.
AffirmedRx, a public benefit corporation, aims to bring transparency to the PBM industry by disclosing all financial terms to clients. Baker discussed their unique approach, which includes a cloud-based system, patient care advocates, and a clinically-driven formulary that prioritizes cost-effectiveness and clinical utility over rebates.
He expressed skepticism about legislative solutions, suggesting that current proposals may not address the root causes of industry issues. AffirmedRx is part of TransparencyRx, a collective advocating for industry reform.
Looking ahead, Baker warned against the proliferation of corporate entities within PBMs, which could further obscure pricing practices and hinder transparency efforts. He underscored the importance of educating stakeholders and advocating for meaningful reform within the industry.
The 2024 Asembia Meeting is Underway
April 29th 2024GLP-1s, artificial intelligence and the Inflation Reduction Act are among the topics featured in the education sessions of the specialty pharmacy meeting in Las Vegas. The keynote speaker is William McRaven, a retired four-star admiral and former chancellor of the University of Texas system.
Read More
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen